β-Galactosidase-activated theranostic for hepatic carcinoma therapy and imaging

Mrinmoy Maiti, Kai Kikuchi, K. K. Athul, Amandeep Kaur, Sankarprasad Bhuniya

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

A β-galactosidase activatable fluorescent turn-on theranostic Gal-CGem exhibits gemcitabine release specifically in β-galactosidase overexpressing hepatic carcinoma cells. The cytotoxicity of Gal-CGem in cancer cells is achieved through the apoptotic cell death pathway. Overall, Gal-CGem is a new frontline prodrug in cancer therapy that has provided antineoplastic information through fluorescence imaging.

Original languageEnglish
Pages (from-to)6413-6416
Number of pages4
JournalChemical Communications
Volume58
Issue number44
DOIs
Publication statusPublished - 3 May 2022
Externally publishedYes

Cite this